Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trial.

Abstract

Authors

• Ethel D Weld
  The Johns Hopkins University School of Medicine, Baltimore, MD, USA; The Johns Hopkins University School of Medicine Center for Tuberculosis Research, Baltimore, MD, USA. Electronic address: eweld@jhmi.edu.
• Trevor Beattie
  The Aurum Institute, Parktown, South Africa; Department of Interdisciplinary Social Sciences, Utrecht University, Utrecht, Netherlands.
• Jayajothi Moodley
  The Aurum Institute, Parktown, South Africa; Department of Interdisciplinary Social Sciences, Utrecht University, Utrecht, Netherlands.
• Manasa Mapendere
  The Aurum Institute, Parktown, South Africa.
• Isadora Salles
  The Johns Hopkins University School of Medicine Center for Tuberculosis Research, Baltimore, MD, USA.
• Belén P Solans
  University of California San Francisco School of Medicine, San Francisco, CA, USA.
• Bareng A S Nonyane
  The Johns Hopkins University School of Medicine Center for Tuberculosis Research, Baltimore, MD, USA; The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
• Lubbe Wiesner
  Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
• Tanya Nielson
  The Aurum Institute, Parktown, South Africa; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
• Vinodh A Edward
  The Aurum Institute, Parktown, South Africa; Department of Interdisciplinary Social Sciences, Utrecht University, Utrecht, Netherlands; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
• Violet Chihota
  The Aurum Institute, Parktown, South Africa; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
• Radojka M Savic
  University of California San Francisco School of Medicine, San Francisco, CA, USA.
• Kelly E Dooley
  Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
• Richard E Chaisson
  The Johns Hopkins University School of Medicine, Baltimore, MD, USA; The Johns Hopkins University School of Medicine Center for Tuberculosis Research, Baltimore, MD, USA; The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
• Gavin J Churchyard
  The Aurum Institute, Parktown, South Africa; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.

Keywords

No keywords available for this article.

External Resources